SCHEMBL3917067

SCHEMBL3917067

Cc1cc(C)c(C)c(S(=O)(=O)N2CCC3(CC2)NC(Cc2ccccc2)C(=O)N3Cc2ccccc2)c1C

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 4/20 0.39
MAPT P10636 2/20 0.39
EBP Q15125 1/20 0.39
DHCR7 Q9UBM7 1/20 0.39
POLB P06746 1/20 0.38
NR4A1 P22736 1/20 0.38
CXCR3 P49682 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
TSHR P16473 1/20 0.37
CCR5 P51681 2/20 0.37
USP2 O75604 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3926267 0.87 ALDH1A1 (0.47) MEN1KMT2AALDH1A1MAPTUSP2
SCHEMBL3917724 0.85 CYP2D6 (0.51) MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3925408 0.84 SMN1; SMN2 (0.48) MEN1KMT2ALMNASMN1; SMN2ALDH1A1
SCHEMBL3915497 0.84 CYP2D6 (0.50) MEN1KMT2ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL3925412 0.83 ALDH1A1 (0.46) MEN1KMT2ALMNASMN1; SMN2L3MBTL1
SCHEMBL3915453 0.82 HSD11B1 (0.48) MEN1KMT2ALMNASMN1; SMN2L3MBTL1
SCHEMBL3919576 0.81 MMP2 (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3920599 0.81 PKM (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1POLB
SCHEMBL4038204 0.80 EPHX2 (0.47) MEN1KMT2AL3MBTL1ALDH1A1EBP
SCHEMBL3920922 0.80 PKM (0.45) LMNASMN1; SMN2ALDH1A1MAPTCXCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US claimed
EP-1730144-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-06-10 EP claimed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US claimed
US-7560468-B2 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2009-07-14 US disclosed
EP-1730144-B1 SUBSTITUTED 1,4,8-TRIAZASPIRO¬4.5 DECAN-2-ONE COMPOUNDS GRUENENTHAL GMBH (DE) 2009-06-10 EP disclosed
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds GRUENENTHAL GMBH (DE) 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015783-A1 Substituted 1,4,8-triazaspiro[4,5]decan-2-one compounds THPO, UGT1A8, UGT1A4 MEN1 1493/4885KMT2A 4051/4885LMNA 1640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.